Interleukin-7 and interleukin-15 for cancer.
Title | Interleukin-7 and interleukin-15 for cancer. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Zarogoulidis, P., Lampaki S., Yarmus L., Kioumis I., Pitsiou G., Katsikogiannis N., Hohenforst-Schmidt W., Li Q., Huang H., Sakkas A., Organtzis J., Sakkas L., Mpoukovinas I., Tsakiridis K., Lazaridis G., Syrigos K., & Zarogoulidis K. |
Journal | J Cancer |
Volume | 5 |
Issue | 9 |
Pagination | 765-73 |
Date Published | 2014 |
ISSN | 1837-9664 |
Abstract | Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer. |
DOI | 10.7150/jca.10471 |
Alternate Journal | J Cancer |
PubMed ID | 25368677 |
PubMed Central ID | PMC4216801 |